The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-03-01 Epub Date: 2024-01-15 DOI:10.1097/MPA.0000000000002291

Satoru Abe, Yousuke Nakai, Junichi Arita, Akihiko Ichida, Yoshikuni Kawaguchi, Nobuhisa Akamatsu, Junichi Kaneko, Hideaki Ijichi, Kazuhiko Koike, Mitsuhiro Fujishiro, Kiyoshi Hasegawa

{"title":"The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection.","authors":"Satoru Abe, Yousuke Nakai, Junichi Arita, Akihiko Ichida, Yoshikuni Kawaguchi, Nobuhisa Akamatsu, Junichi Kaneko, Hideaki Ijichi, Kazuhiko Koike, Mitsuhiro Fujishiro, Kiyoshi Hasegawa","doi":"10.1097/MPA.0000000000002291","DOIUrl":null,"url":null,"abstract":"Objectives: The local renin-angiotensin system promotes angiogenesis and proliferation via vascular endothelial growth factor or epidermal growth factor receptor expression. In this study, we aimed to evaluate the impact of angiotensin system inhibitors (ASIs) on long-term outcomes in patients undergoing surgical resection of pancreatic ductal adenocarcinoma (PDAC).Methods: A single institutional retrospective analysis was performed using the medical records of patients who underwent pancreatic resection with curative intent for PDAC between January 2005 and December 2018. Patient characteristics and surgical outcomes were compared between patients taking ASIs and those who are not.Results: A total of 272 patients were included in the study and classified into the ASI group (n = 121) and the non-ASI group (n = 151). The median overall survival times in the ASI group and non-ASI group were 38.0 and 34.0 months ( P = 0.250), and the median recurrence-free survival times were 24.0 and 15.0 months ( P = 0.025), respectively. Multivariate analysis for recurrence-free survival identified the use of ASIs ( P = 0.020), CA19-9 level >500 IU/L ( P = 0.010), positive lymph node metastasis ( P < 0.001), and no adjuvant chemotherapy ( P < 0.001) as independent prognostic factors.Conclusions: The use of ASI may improve long-term outcomes after surgery for PDAC.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002291","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The local renin-angiotensin system promotes angiogenesis and proliferation via vascular endothelial growth factor or epidermal growth factor receptor expression. In this study, we aimed to evaluate the impact of angiotensin system inhibitors (ASIs) on long-term outcomes in patients undergoing surgical resection of pancreatic ductal adenocarcinoma (PDAC).

Methods: A single institutional retrospective analysis was performed using the medical records of patients who underwent pancreatic resection with curative intent for PDAC between January 2005 and December 2018. Patient characteristics and surgical outcomes were compared between patients taking ASIs and those who are not.

Results: A total of 272 patients were included in the study and classified into the ASI group (n = 121) and the non-ASI group (n = 151). The median overall survival times in the ASI group and non-ASI group were 38.0 and 34.0 months ( P = 0.250), and the median recurrence-free survival times were 24.0 and 15.0 months ( P = 0.025), respectively. Multivariate analysis for recurrence-free survival identified the use of ASIs ( P = 0.020), CA19-9 level >500 IU/L ( P = 0.010), positive lymph node metastasis ( P < 0.001), and no adjuvant chemotherapy ( P < 0.001) as independent prognostic factors.

Conclusions: The use of ASI may improve long-term outcomes after surgery for PDAC.

查看原文本刊更多论文

肾素-血管紧张素系统抑制剂对胰腺癌切除术患者的影响

目的：局部肾素-血管紧张素系统通过血管内皮生长因子或表皮生长因子受体的表达促进血管生成和增殖。本研究旨在评估血管紧张素系统抑制剂（ASI）对接受胰腺导管腺癌（PDAC）手术切除患者长期预后的影响：利用2005年1月至2018年12月期间因PDAC接受胰腺根治性切除术的患者的病历资料进行了一项单一机构回顾性分析。比较了服用ASI和未服用ASI的患者的特征和手术结果：研究共纳入272名患者，分为ASI组（n = 121）和非ASI组（n = 151）。ASI组和非ASI组的中位总生存时间分别为38.0个月和34.0个月（P=0.250），中位无复发生存时间分别为24.0个月和15.0个月（P=0.025）。无复发生存期的多变量分析表明，使用ASI（P = 0.020）、CA19-9水平>500 IU/L（P = 0.010）、淋巴结转移阳性（P < 0.001）和未进行辅助化疗（P < 0.001）是独立的预后因素：结论：ASI的使用可改善PDAC术后的长期预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.